Deals this week: Nordic Nanovector ASA, Charles River Laboratories International, Transgene SA

13th October 2016 (Last Updated October 13th, 2016 18:30)

Nordic Nanovector ASA and LegoChem Biosciences have entered an agreement to include CD37-targeting antibody drug conjugates to non-radionuclide cancer drugs.

Nordic Nanovector ASA and LegoChem Biosciences have entered an agreement to include CD37-targeting antibody drug conjugates to non-radionuclide cancer drugs.

The partnership allows Nordic Nanovector to strengthen its pipeline products for targeted therapies and also develop novel antibody drug conjugates (ADCs) for the treatment of leukaemia.

Charles River Laboratories International and Genentech have extended their co-development agreement for integrated drug discovery.

According to the agreement, Charles River will be responsible for providing early drug discovery services such as medicinal chemistry, structural biology, in vitro and in vivo biology and computer-aided drug design.

The agreement enables the two partners to identify early stage molecules for pre-clinical development.

Transgene SA, Merck and Pfizer have entered an agreement to examine the efficacy of the therapeutic vaccine TG4001 in combination with avelumab in the treatment of human papilloma virus-(HPV) positive head and neck cancer.

Pursuant to the agreement, Transgene will be responsible for sponsoring the phase I/II trials to evaluate the combination of TG4001 and avelumab.

The agreement enables the partners to develop a novel therapy for the treatment of HPV- positive head and neck squamous cell carcinoma.

Eris Lifesciences plans to raise gross proceeds of $300 million through the initial public offering (IPO) of its shares.

Axis Capital, Credits Suisse Securities (India) and Citigroup Global Markets India are acting as financial advisors for the offering.

"Charles River Laboratories International and Genentech have extended their co-development agreement for integrated drug discovery."

ChrysCapital Management Company, a 16% stakeholder in Eris Lifesciences, will sell its shares in the offering to exit the partnership.

Piramal Enterprises plans to strengthen its injectable anaesthesia and pain management product portfolio by acquiring five anaesthesia and pain management products from Janssen Pharmaceutical NV.

According to the agreement, Piramal will be responsible for paying an upfront payment of $155 million to Janssen and also an additional $20 million based on certain financial milestones of the product achieved over the next 30 months.

Janssen Pharmaceutical will be responsible for marketing and selling the products until the relevant business relation and marketing authorisation rights are completely transferred to Piramal.


Image: Transgene SA, Merck and Pfizer have entered an agreement to examine the efficacy of the therapeutic vaccine TG4001 in combination with avelumab. Photo: Courtesy of Lauri Silvennoinen.